Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06442800 · ClinicalTrials.gov registry record · NA
Impacts of Alcohol Warning Labels: An Online Experiment
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 1,123
- Enrollment target
NCT06442800: Completed NA study, sponsored by University of North Carolina, Chapel Hill.
NCT06442800 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 1,123 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06442800, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,123 participants
- Enrollment target
Study Summary
The goal of this experiment is to examine responses to alcohol warning messages about 10 different topics among US adult alcohol consumers. The main questions this experiment aims to answer are: Which warning topics make alcohol consumers in the US want to drink less alcohol? Which warning topics remind alcohol consumers in the US of alcohol's harms? Which warning topics help alcohol consumers in the US learn something new? There will be a total of 20 alcohol messages, 2 messages for each of the 10 topics. For each topic, participants will be randomly assigned to 1 of the 2 messages so that they view a total of 10 alcohol messages. All 10 messages will be shown in random order. Participants will rate each message on how much it makes them want to drink less alcohol, reminds them that drinking can be harmful, and teaches them something new.
Primary Outcome
The study will assess perceived message effectiveness using 1 item: "How much does this message make you want to drink less alcohol?" Response options will range from "not at all" (coded as 1) to "a great deal" (coded as 5). Higher scores indicate more perceived message effectiveness. Survey weighted means are reported to account for NORC AmeriSpeak's sampling design to enable results to be statistically representative of the US population of drinkers age \>/=21 who drink alcohol.
Interventions
- BEHAVIORAL Colorectal Cancer
- BEHAVIORAL Liver Cancer
- BEHAVIORAL Throat and Mouth Cancer
- BEHAVIORAL Multiple Cancers
- BEHAVIORAL Liver Disease
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,123 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2024-10-14 |
| Phase | NA |
What the finished NCT06442800 record still lists
NCT06442800 is an interventional study that assigns participants to a tested intervention. Its 1,123 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 5 interventions - of which Colorectal Cancer is the first listed.
NCT06442800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06442800 about?
NCT06442800 is a clinical study titled "Impacts of Alcohol Warning Labels: An Online Experiment". The goal of this experiment is to examine responses to alcohol warning messages about 10 different topics among US adult alcohol consumers. The main questions this experiment aims to answer are: Which warning topics make alcohol consumers in the US want to drink less alcohol? Which warning topics r...
What is the current status of trial NCT06442800?
This trial is currently completed. It is a NA study. The enrollment target is 1,123 participants. The study started on 2024-09-25. Estimated completion is 2024-10-14.
What interventions are being tested in trial NCT06442800?
The interventions under investigation include: Colorectal Cancer (BEHAVIORAL), Liver Cancer (BEHAVIORAL), Throat and Mouth Cancer (BEHAVIORAL), Multiple Cancers (BEHAVIORAL), Liver Disease (BEHAVIORAL).
Who is sponsoring clinical trial NCT06442800?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06442800's enrollment target sits among peer trials
1,123 93rd of 2000 higher than 1,908 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05438329 · 1,123 participants · Phase 1
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
- NCT06952504 · 1,123 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
- NCT04421768 · 1,125 participants · NA
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI